Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSecond Affiliated Hospital of Guangzhou Medical University
About this trial
The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-T cells for immunotherapy of human cancer patients with Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the Mesothelin-CAR-T cell immunotherapy on human cancers will firstly be evaluated.
Eligibility criteria
Qualifiers
None
Disqualifiers
Had accepted gene therapy before;
Severe virus infection such as HBV, HCV, HIV, et al;
Known HIV positivity;
Active infectious disease related to bacteria, virus,fungi,et al;
Trial design
Treatments tested in this trial
- CAR-T cells
Treatment groups
No treatment groups listed
Sponsors and collaborators
Second Affiliated Hospital of Guangzhou Medical University
Lead sponsor
Fapon Biotherapy Inc.
Collaborator
Source ClinicalTrials.gov